Latest Breaking News On - Gastroesophageal junction - Page 6 : comparemela.com

Astellas Submits New Drug Application for Zolbetuximab in Japan

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the submission of a New Drug Application (NDA).

United statesUnited kingdomNaoki okamuraPranob bhattacharyaAmerican cancer societyNational cancer instituteMinistry of healthAstellas pharma incOncology developmentEnd results programDrug application to japan ministry of healthPrnewswire astellas pharma incAmerican society of clinical oncologyJapan ministry of healthNew drug applicationExecutive director

Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023

– Data Across 30 Abstracts Reinforce Leadership in Metastatic Breast Cancer and Demonstrate Breadth of Pipeline Across Lung, Hematologic, Genitourinary, Gastrointestinal, Gynecological and. | May 17, 2023

Foster cityUnited statesDomvanalimab domPembrolizumab pembroEtrumadenant etrumaAxicabtagene ciloleucelZimberelimab zimFrank neumannSanta monicaBrexucabtagene autoleucel brexuGilead sciencesDrug administrationGilead sciences incGilead companyAmerican society of clinical oncologyKite global head of clinical development

Results from Astellas Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet

Results from Astellas Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomPranob bhattacharyaNaoki okamuraKohei shitaraAstellas pharma incDepartment of gastrointestinal oncologyNational cancer instituteAmerican cancer societyPrnewswire astellas pharma incEnd results programNational cancer center hospitalOncology developmentAmerican society of clinical oncologyClinical oncologyPrimary investigator

Results from Astellas Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that The Lancet published detailed data from the.

United kingdomUnited statesPranob bhattacharyaNaoki okamuraKohei shitaraAmerican cancer societyEnd results programDepartment of gastrointestinal oncologyAstellas pharma incAmerican society of clinical oncologyPrnewswire astellas pharma incOncology developmentNational cancer center hospitalNational cancer instituteClinical oncologyPrimary investigator

Results from Astellas Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet

Results from Astellas Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesPranob bhattacharyaNaoki okamuraKohei shitaraOncology developmentAstellas pharma incDepartment of gastrointestinal oncologyNational cancer instituteAmerican cancer societyEnd results programNational cancer center hospitalAmerican society of clinical oncologyPrnewswire astellas pharma incClinical oncologyPrimary investigator